RxDoctor Payments Data

Lampros Papadimitriou, MD

Advanced Heart Failure and Transplant Cardiology · Jackson, MSNPI 1205322385

Payments from drug & device makers

$223,737in general payments, 2019–2025

Across 364 payments — averaging $614.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$154K
  • Applied Therapeutics, Inc.$62K
  • Abbott$1K
  • Pfizer$831
  • Novartis$713
  • Boehringer Ingelheim$620
  • plus $4K from 31 others

What the payments were for

  • Speaking & faculty fees$2002%
  • Travel & lodging$1,59218%
  • Food & beverage$6,73778%
  • Education$1622%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few advanced heart failure and transplant cardiology providers in Mississippito place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$105,701
Medicare patients
330
Services billed
1,142

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan317$255,858
FarxigaDapagliflozin Propanediol231$153,507
JardianceEmpagliflozin145$96,872
Ambrisentan29$92,953
EliquisApixaban84$57,735
Tadalafil13$35,834
XareltoRivaroxaban24$24,358
VerquvoVericiguat17$12,419
Tacrolimus47$10,719
CorlanorIvabradine Hcl15$9,867
Mycophenolate Mofetil60$8,039
DapagliflozinDapagliflozin Propanediol14$6,461
Sirolimus13$5,247
Potassium Chloride95$4,206
Isosorbide Dinitrate75$3,654

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$713$255,858317 claims
AstraZenecaFarxiga$349$153,507231 claims
Boehringer IngelheimJardiance$620$96,872145 claims
PfizerEliquis$831$57,73584 claims
Johnson & JohnsonXarelto$376$24,35824 claims
MerckVerquvo$154,049$12,41917 claims
AmgenCorlanor$74$9,86715 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few advanced heart failure and transplant cardiology providers in Mississippion file to place this against a meaningful peer group, so we don't.

Other advanced heart failure and transplant cardiology in Jackson

Where these figures come from

Is this you, or does something look wrong? →